Health Ministry set to roll out free HPV vaccination plan targeting girls aged 14

Excellent — rich Tier 1 (PIB) data retrieved. Proceeding to write the full study note.

HPV Vaccination Programme — Free Nationwide Rollout (Girls Aged 14)

UPSC Prelims + Mains Study Note

1. At a Glance

• Human Papillomavirus (HPV) vaccination is being rolled out nationally by India's Union Health Ministry, targeting girls aged 14, free of cost at government facilities. [S1]
• Cervical cancer is the second most common cancer among women in India; HPV types 16 and 18 are responsible for the majority of cases. [S2]
• India joins 160+ countries that have included HPV vaccination in their national immunisation schedules, aligning with the WHO cervical cancer elimination goal. [S1]
• Critical for UPSC: intersects GS-II (health policy, government schemes), GS-III (science & tech — vaccines), and social equity dimensions (gender, access). [S1][S3]

2. Why in the News

• February 25, 2026: Union Health Ministry announced the imminent nationwide rollout — reported as front-page news in The Hindu. [S4]
• February 28, 2026: Prime Minister Narendra Modi formally launched the programme from Ajmer, Rajasthan; all States/UTs held simultaneous launch events on the same day. [S1]
• March 2026: PIB issued an update on the National HPV Vaccination Programme status. [S5]
• The launch follows a Union Budget 2024-25 announcement by Finance Minister Nirmala Sitharaman, who had flagged cervical cancer vaccination under 'Nari Shakti' priorities. [S6]

3. Background & Evolution

• Earlier initiative: India's Universal Immunisation Programme (UIP) did not originally include HPV vaccine; this rollout is its formal induction into UIP for the 14-year age cohort.
• Preceding campaigns: States like Sikkim, Punjab, Delhi ran limited HPV vaccination pilots before the national rollout.
• WHO's 90-70-90 target (90% girls vaccinated, 70% screened, 90% treated) by 2030 is the strategic framework driving India's decision. [S3]

4. Core Static Facts

The Vaccine - Name: Gardasil (quadrivalent — Gardasil-4) - Manufacturer: Merck & Co. (USA) - HPV types covered: 6, 11 (genital warts) and 16, 18 (cervical cancer) [S4] - Dosing regimen: Single dose for the 14-year target cohort (globally validated efficacy) [S4] - Effectiveness: 93–100% against HPV strains responsible for cervical cancer [S1]

Programme Parameters - Target group: Girls aged 14 years [S4] - Target beneficiaries: Approximately 1.15 crore girls annually [S1] - Cost to beneficiary: Free of cost [S4] - Delivery sites: Exclusively designated government health facilities — Ayushman Arogya Mandirs (PHCs), Community Health Centres (CHCs), Sub-District hospitals [S4] - Voluntary or mandatory: Voluntary [S4] - Geographic scope: All States and Union Territories of India [S1]

Implementing Bodies - Nodal Ministry: Ministry of Health and Family Welfare (MoHFW) - Procurement partner: Gavi, the Vaccine Alliance (international partnership) [S4] - Drug regulatory approval: CDSCO (Central Drugs Standard Control Organisation) has approved Gardasil [S4] - Programme launched by: Prime Minister Narendra Modi, Ajmer, Rajasthan, February 28, 2026 [S1] - Cold chain standard: Stringent cold chain logistics mandated for quality assurance [S4]

Disease Burden Context - Cervical cancer = 2nd most common cancer in Indian women [S1] - Globally, cervical cancer is the 4th most common cancer in women [S3] - HPV 16 and 18 together account for approximately 70% of all cervical cancer cases globally [S3]

5. Multi-Dimensional Analysis

Social / Gender

• Targets girls aged 14 — pre-sexual debut intervention window maximises immunological benefit and ensures prophylactic (not therapeutic) effect. [S4]
• Free and voluntary delivery ensures reach across socio-economic groups, addressing equity gaps in cancer care access. [S4]
• Cervical cancer disproportionately affects low-income women with limited access to screening (Pap smear, VIA, HPV DNA tests). [S3]
• Converges with Poshan Abhiyaan, WIFS (Weekly Iron and Folic Acid Supplementation), and adolescent girl health schemes delivered through the same health facility network.

Scientific / Technological

• Quadrivalent vaccine (types 6, 11, 16, 18) versus bivalent (types 16, 18 only) — Gardasil-4 provides broader protection including genital wart prevention. [S4]
• Shift to single-dose schedule (from earlier 2-dose for under-15) is backed by WHO's 2022 updated guidelines, reducing programme complexity and cost. [S1]
• Cold chain dependency: HPV vaccine is thermosensitive, requiring 2–8°C storage — logistical challenge for remote areas.
• Domestic manufacturing gap: India does not yet produce an indigenously manufactured quadrivalent HPV vaccine at scale (SII's Cervavac is bivalent; Gardasil is imported via Gavi).

Economic

• Gavi partnership enables below-market procurement pricing, making free delivery fiscally viable. [S4]
• Cervical cancer treatment costs are a catastrophic out-of-pocket burden; prevention through vaccination has high cost-effectiveness ratio (DALYs averted per dollar).
• Burden on Ayushman Bharat's hospitalisation fund is expected to decline long-term if coverage targets are met.

Administrative

• Delivery piggybacks on existing Universal Immunisation Programme (UIP) cold chain and ASHA/ANM outreach networks. [S1]
• Coordination challenge: 14-year-old girls are largely in schools (Class 8–9), requiring MoHFW-MoE convergence for school-based vaccination camps.
• Ayushman Arogya Mandirs (renamed from Health and Wellness Centres) are the frontline delivery point — their functional readiness is critical. [S4]

Legal / Constitutional

• Right to health is implied under Article 21 (right to life and personal dignity) — free vaccination operationalises this constitutional guarantee.
• Drug regulation under the Drugs and Cosmetics Act, 1940 — Gardasil's CDSCO approval is the statutory prerequisite for national deployment. [S4]

Ethical / Governance

• Voluntary nature addresses consent ethics; avoids coercion concerns in a sensitive adolescent health context. [S4]
• Transparent Gavi procurement mechanism guards against corruption in high-value vaccine procurement. [S4]
• Potential tension: Religious/social resistance to HPV vaccine (perceived as sexual health intervention) can undermine uptake — communication strategy is critical.

6. Recent Developments (Last 12–18 Months)

• February 2024: Union Budget 2024-25 — FM Sitharaman announced cervical cancer vaccination as a government priority under 'Nari Shakti'. [S6]
• 2025: India formalises partnership with Gavi, the Vaccine Alliance for Gardasil procurement for the national programme. [S4]
• February 25, 2026: Health Ministry pre-launch announcement; The Hindu reports imminent rollout for girls aged 14. [S4]
• February 28, 2026: PM Modi launches the programme from Ajmer, Rajasthan; simultaneous launches in all States/UTs. [S1]
• March 2026: PIB releases update on programme status and rollout progress across states. [S5]
• Concurrent: Ministry of Health issues directive to States to create awareness about cervical cancer prevention among girl students (earlier PIB release). [S2]

7. Prelims Hooks (High-Density Factual Bullets)

1. The HPV vaccination programme was formally launched by PM Narendra Modi on February 28, 2026, from Ajmer, Rajasthan. [S1]
2. The vaccine used in India's national programme is Gardasil (quadrivalent), covering HPV types 6, 11, 16, and 18. [S4]
3. HPV types 16 and 18 cause the majority of cervical cancer cases; types 6 and 11 cause genital warts. [S4]
4. Target age group under the national programme: 14-year-old girls only. [S4]
5. Number of targeted beneficiaries: approximately 1.15 crore girls per year. [S1]
6. The vaccination is voluntary and free of cost across all States and UTs. [S4]
7. Vaccine is delivered exclusively at government health facilities (not private). [S4]
8. Delivery facilities include Ayushman Arogya Mandirs (formerly Health and Wellness Centres), CHCs, and Sub-District Hospitals. [S4]
9. India procures Gardasil in partnership with Gavi, the Vaccine Alliance — an international vaccine financing body. [S4]
10. Single-dose schedule is used for the 14-year cohort — 93–100% effective against cancer-causing HPV strains. [S1]
11. Cervical cancer is the second most common cancer among women in India. [S1]
12. With this launch, India joins 160+ countries that have HPV vaccination in their national immunisation schedules. [S1]
13. Over 90 countries globally have adopted the single-dose HPV vaccination schedule. [S1]
14. The cervical cancer vaccination initiative was first announced in Union Budget 2024-25 by FM Sitharaman under 'Nari Shakti'. [S6]
15. Gardasil is approved by CDSCO (India's drug regulator); it is not manufactured domestically at the quadrivalent level. [S4]

8. Mains Relevance

GS Paper Mapping

Plausible Mains Question Stems

1. "India's free nationwide HPV vaccination programme is a significant step toward cervical cancer elimination. Critically examine the challenges in achieving full coverage and the role of public health infrastructure in its success." (GS-II, 15 marks)
2. "Assess the importance of India's partnership with Gavi, the Vaccine Alliance, in ensuring equitable access to HPV vaccines. What are the implications for India's long-term vaccine self-reliance?" (GS-II / GS-III, 10 marks)
3. "Discuss how voluntary immunisation programmes targeted at adolescent girls can serve as instruments of gender equity and preventive healthcare in India." (GS-I / GS-II, 15 marks)

9. Related Topics to Study Next

10. Common Errors / Trap Areas

1. Wrong target age: Aspirants may confuse the target age with WHO's recommended range of 9–14 years. India's national programme specifically targets 14-year-old girls — not 9–13 or 9–26. [S4]
2. Wrong vaccine type: Confusing Gardasil (quadrivalent, 4-valent) with Cervarix (bivalent, GlaxoSmithKline) or SII's Cervavac (also bivalent). India's national programme uses Gardasil-4, not Cervavac. [S4]
3. Mandatory vs. Voluntary: A common exam trap — India's programme is explicitly voluntary, not mandatory. [S4]
4. Wrong launch location: Programme launched from Ajmer, Rajasthan — not Delhi or any other city. Exam questions sometimes test launch venues. [S1]
5. Confusing HPV types: Types 16 & 18 → cervical cancer; types 6 & 11 → genital warts. Do not interchange their disease associations. [S4]
6. Ministry confusion: Implementing ministry is Ministry of Health and Family Welfare (MoHFW) — not Ministry of Women and Child Development (MoWCD), though adolescent girl schemes often involve MoWCD.

11. Sources

• [S1] "Prime Minister Shri Narendra Modi Launches Nationwide HPV Vaccination Drive for 14-Year-Old Girls from Ajmer, Rajasthan" — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2233906 — (Tier 1)
• [S2] "Centre urges States to create awareness and take steps for prevention of cervical cancer among girl students" — https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=1885597 — (Tier 1)
• [S3] "Elimination Planning Tool: Advancing Towards Cervical Cancer Elimination — India" — https://gco.iarc.who.int/media/elimination_tool/factsheets/356-IND-india.pdf — (Tier 2, WHO/IARC)
• [S4] "Health Ministry set to roll out free HPV vaccination plan targeting girls aged 14" — The Hindu, February 25, 2026 (article excerpt supplied as primary source) — https://www.thehindu.com/todays-paper/2026-02-25/th_international/articleGQUFKRFJH-13644549.ece — (Tier 4)
• [S5] "Update on National HPV Vaccination Programme" — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2241079 — (Tier 1)
• [S6] "'Nari Shakti' Takes Centre Stage; Union Finance Minister Announces Vaccination to Prevent Cervical Cancer" — https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2001172 — (Tier 1)